Dmitri Parkhomchuk
Max Planck Society
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Dmitri Parkhomchuk.
Science | 2008
Marc Sultan; Marcel H. Schulz; Hugues Richard; Alon Magen; Andreas Klingenhoff; Matthias Scherf; Martin Seifert; Tatjana Borodina; Aleksey Soldatov; Dmitri Parkhomchuk; Dominic Schmidt; Sean O'Keeffe; Stefan A. Haas; Martin Vingron; Hans Lehrach; Marie-Laure Yaspo
The functional complexity of the human transcriptome is not yet fully elucidated. We report a high-throughput sequence of the human transcriptome from a human embryonic kidney and a B cell line. We used shotgun sequencing of transcripts to generate randomly distributed reads. Of these, 50% mapped to unique genomic locations, of which 80% corresponded to known exons. We found that 66% of the polyadenylated transcriptome mapped to known genes and 34% to nonannotated genomic regions. On the basis of known transcripts, RNA-Seq can detect 25% more genes than can microarrays. A global survey of messenger RNA splicing events identified 94,241 splice junctions (4096 of which were previously unidentified) and showed that exon skipping is the most prevalent form of alternative splicing.
Nucleic Acids Research | 2009
Dmitri Parkhomchuk; Tatiana Borodina; Vyacheslav Amstislavskiy; Maria Banaru; Linda Hallen; Sylvia Krobitsch; Hans Lehrach; Alexey Soldatov
High-throughput complementary DNA sequencing (RNA-Seq) is a powerful tool for whole-transcriptome analysis, supplying information about a transcripts expression level and structure. However, it is difficult to determine the polarity of transcripts, and therefore identify which strand is transcribed. Here, we present a simple cDNA sequencing protocol that preserves information about a transcripts direction. Using Saccharomyces cerevisiae and mouse brain transcriptomes as models, we demonstrate that knowing the transcripts orientation allows more accurate determination of the structure and expression of genes. It also helps to identify new genes and enables studying promoter-associated and antisense transcription. The transcriptional landscapes we obtained are available online.
PLOS ONE | 2009
Michal R. Schweiger; Martin Kerick; Bernd Timmermann; Marcus W. Albrecht; Tatjana Borodina; Dmitri Parkhomchuk; Kurt Zatloukal; Hans Lehrach
Background Cancer re-sequencing programs rely on DNA isolated from fresh snap frozen tissues, the preparation of which is combined with additional preservation efforts. Tissue samples at pathology departments are routinely stored as formalin-fixed and paraffin-embedded (FFPE) samples and their use would open up access to a variety of clinical trials. However, FFPE preparation is incompatible with many down-stream molecular biology techniques such as PCR based amplification methods and gene expression studies. Methodology/Principal Findings Here we investigated the sample quality requirements of FFPE tissues for massively parallel short-read sequencing approaches. We evaluated key variables of pre-fixation, fixation related and post-fixation processes that occur in routine medical service (e.g. degree of autolysis, duration of fixation and of storage). We also investigated the influence of tissue storage time on sequencing quality by using material that was up to 18 years old. Finally, we analyzed normal and tumor breast tissues using the Sequencing by Synthesis technique (Illumina Genome Analyzer, Solexa) to simultaneously localize genome-wide copy number alterations and to detect genomic variations such as substitutions and point-deletions and/or insertions in FFPE tissue samples. Conclusions/Significance The application of second generation sequencing techniques on small amounts of FFPE material opens up the possibility to analyze tissue samples which have been collected during routine clinical work as well as in the context of clinical trials. This is in particular important since FFPE samples are amply available from surgical tumor resections and histopathological diagnosis, and comprise tissue from precursor lesions, primary tumors, lymphogenic and/or hematogenic metastases. Large-scale studies using this tissue material will result in a better prediction of the prognosis of cancer patients and the early identification of patients which will respond to therapy.
Nature Genetics | 2015
Philipp G. Maass; Atakan Aydin; Friedrich C. Luft; Carolin Schächterle; Anja Weise; Sigmar Stricker; Carsten Lindschau; Martin Vaegler; Fatimunnisa Qadri; Hakan R. Toka; Herbert Schulz; Peter Krawitz; Dmitri Parkhomchuk; Jochen Hecht; Irene Hollfinger; Yvette Wefeld-Neuenfeld; Eireen Bartels-Klein; Astrid Mühl; Martin Kann; Herbert Schuster; David Chitayat; Martin G. Bialer; Thomas F. Wienker; Jurg Ott; Katharina Rittscher; Thomas Liehr; Jens Jordan; Ghislaine Plessis; Jens Tank; Knut Mai
Cardiovascular disease is the most common cause of death worldwide, and hypertension is the major risk factor. Mendelian hypertension elucidates mechanisms of blood pressure regulation. Here we report six missense mutations in PDE3A (encoding phosphodiesterase 3A) in six unrelated families with mendelian hypertension and brachydactyly type E (HTNB). The syndrome features brachydactyly type E (BDE), severe salt-independent but age-dependent hypertension, an increased fibroblast growth rate, neurovascular contact at the rostral-ventrolateral medulla, altered baroreflex blood pressure regulation and death from stroke before age 50 years when untreated. In vitro analyses of mesenchymal stem cell–derived vascular smooth muscle cells (VSMCs) and chondrocytes provided insights into molecular pathogenesis. The mutations increased protein kinase A–mediated PDE3A phosphorylation and resulted in gain of function, with increased cAMP-hydrolytic activity and enhanced cell proliferation. Levels of phosphorylated VASP were diminished, and PTHrP levels were dysregulated. We suggest that the identified PDE3A mutations cause the syndrome. VSMC-expressed PDE3A deserves scrutiny as a therapeutic target for the treatment of hypertension.
Blood | 2013
Peter Krawitz; Britta Höchsmann; Yoshiko Murakami; Britta Teubner; Ulrike Krüger; Eva Klopocki; Heidemarie Neitzel; Alexander Hoellein; Christina Schneider; Dmitri Parkhomchuk; Jochen Hecht; Peter N. Robinson; Stefan Mundlos; Taroh Kinoshita; Hubert Schrezenmeier
To ascertain the genetic basis of a paroxysmal nocturnal hemoglobinuria (PNH) case without somatic mutations in PIGA, we performed deep next-generation sequencing on all exons of known genes of the glycosylphosphatidylinositol (GPI) anchor synthesis pathway. We identified a heterozygous germline splice site mutation in PIGT and a somatic 8-MB deletion in granulocytes affecting the other copy of PIGT. PIGA is essential for GPI anchor synthesis, whereas PIGT is essential for attachment of the preassembled GPI anchor to proteins. Although a single mutation event in the X-chromosomal gene PIGA is known to cause GPI-anchored protein deficiency, 2 such hits are required in the autosomal gene PIGT. Our data indicate that PNH can occur even in the presence of fully assembled GPI if its transfer to proteins is defective in hematopoietic stem cells.
PLOS ONE | 2013
Tom Kamphans; Peggy Sabri; Na Zhu; Verena Heinrich; Stefan Mundlos; Peter N. Robinson; Dmitri Parkhomchuk; Peter Krawitz
The identification of disease-causing mutations in next-generation sequencing (NGS) data requires efficient filtering techniques. In patients with rare recessive diseases, compound heterozygosity of pathogenic mutations is the most likely inheritance model if the parents are non-consanguineous. We developed a web-based compound heterozygous filter that is suited for data from NGS projects and that is easy to use for non-bioinformaticians. We analyzed the power of compound heterozygous mutation filtering by deriving background distributions for healthy individuals from different ethnicities and studied the effectiveness in trios as well as more complex pedigree structures. While usually more then 30 genes harbor potential compound heterozygotes in single exomes, this number can be markedly reduced with every additional member of the pedigree that is included in the analysis. In a real data set with exomes of four family members, two sisters affected by Mabry syndrome and their healthy parents, the disease-causing gene PIGO, which harbors the pathogenic compound heterozygous variants, could be readily identified. Compound heterozygous filtering is an efficient means to reduce the number of candidate mutations in studies aiming at identifying recessive disease genes in non-consanguineous families. A web-server is provided to make this filtering strategy available at www.gene-talk.de.
Genome Medicine | 2013
Verena Heinrich; Tom Kamphans; Jens Stange; Dmitri Parkhomchuk; Jochen Hecht; Thorsten Dickhaus; Peter N. Robinson; Peter Krawitz
With exome sequencing becoming a tool for mutation detection in routine diagnostics there is an increasing need for platform-independent methods of quality control. We present a genotype-weighted metric that allows comparison of all the variant calls of an exome to a high-quality reference dataset of an ethnically matched population. The exome-wide genotyping accuracy is estimated from the distance to this reference set, and does not require any further knowledge about data generation or the bioinformatics involved. The distances of our metric are visualized by non-metric multidimensional scaling and serve as an intuitive, standardizable score for the quality assessment of exome data.
Molecular Genetics & Genomic Medicine | 2014
Peter Krawitz; Daniela Schiska; Ulrike Krüger; Sandra Appelt; Verena Heinrich; Dmitri Parkhomchuk; Bernd Timmermann; José M. Millán; Peter N. Robinson; Stefan Mundlos; Jochen Hecht; Manfred Gross
Usher syndrome is an autosomal recessive disorder characterized both by deafness and blindness. For the three clinical subtypes of Usher syndrome causal mutations in altogether 12 genes and a modifier gene have been identified. Due to the genetic heterogeneity of Usher syndrome, the molecular analysis is predestined for a comprehensive and parallelized analysis of all known genes by next‐generation sequencing (NGS) approaches. We describe here the targeted enrichment and deep sequencing for exons of Usher genes and compare the costs and workload of this approach compared to Sanger sequencing. We also present a bioinformatics analysis pipeline that allows us to detect single‐nucleotide variants, short insertions and deletions, as well as copy number variations of one or more exons on the same sequence data. Additionally, we present a flexible in silico gene panel for the analysis of sequence variants, in which newly identified genes can easily be included. We applied this approach to a cohort of 44 Usher patients and detected biallelic pathogenic mutations in 35 individuals and monoallelic mutations in eight individuals of our cohort. Thirty‐nine of the sequence variants, including two heterozygous deletions comprising several exons of USH2A, have not been reported so far. Our NGS‐based approach allowed us to assess single‐nucleotide variants, small indels, and whole exon deletions in a single test. The described diagnostic approach is fast and cost‐effective with a high molecular diagnostic yield.
Gene | 2016
Julia Hentschel; Dana Tatun; Dmitri Parkhomchuk; Ingo Kurth; Bettina Schimmel; Roswitha Heinrich-Weltzien; Sabine Bertzbach; Hartmut Peters; Christian Beetz
Amelogenesis imperfecta (AI) is a clinically and genetically heterogeneous disorder of tooth development which is due to aberrant deposition or composition of enamel. Both syndromic and isolated forms exist; they may be inherited in an X-linked, autosomal recessive, or autosomal dominant manner. WDR72 is one of ten currently known genes for recessive isolated AI; nine WDR72 mutations affecting single nucleotides have been described to date. Based on whole exome sequencing in a large consanguineous AI pedigree, we obtained evidence for presence of a multi-exonic WDR72 deletion. A home-made multiplex ligation-dependent probe amplification assay was used to confirm the aberration, to narrow its extent, and to identify heterozygous carriers. Our study extends the mutational spectrum for WDR72 to include large deletions, and supports a relevance of the previously proposed loss-of-function mechanism. It also introduces an easy-to-use and highly sensitive tool for detecting WDR72 copy number alterations.
Cancer Cell | 2013
Joachim Weischenfeldt; Ronald Simon; Lars Feuerbach; Karin Schlangen; Dieter Weichenhan; Sarah Minner; Daniela Wuttig; Hans Jörg Warnatz; Henning Stehr; Tobias Rausch; Natalie Jäger; Lei Gu; Olga Bogatyrova; Adrian M. Stütz; Rainer Claus; Jürgen Eils; Roland Eils; Clarissa Gerhäuser; Po Hsien Huang; Barbara Hutter; Rolf Kabbe; Christian Lawerenz; S. Radomski; Cynthia C. Bartholomae; Maria Fälth; Stephan Gade; Manfred Schmidt; Nina Amschler; Thomas Haß; Rami Galal